American study: differences between smokers and non-smokers in kidney cancer

Jun 16, 2022 Leave a message

Researchers from the University of Cincinnati (UC) have identified certain differences between smokers and non-smokers with kidney cancer, highlighting the need for specialized treatment.

The study, "Metabolic Reprogramming in Smoking-induced renal cell Carcinoma," was published in the Journal of Clinical Investigation and identifies the need to develop personalized treatments for patients with this type of cancer.

The tumors from smokers showed up as a separate metabolic subtype of kidney cancer, with its own set of specific genetic vulnerabilities. Building on previous studies that found mutations in kidney cancer cells, the current study found differences in the tumors' metabolic fingerprints that distinguish cancers in nonsmokers from those in smokers.

Led by Maria Czyzyk Krzeska, PhD, professor in the Department of Cancer Biology at the University of California, Jarek Meller, PhD, environmental and Public health Sciences, and Julio Landero Figueroa, PhD, chemistry, a research team analyzed tissue from cancer patients who smoked, It was compared with patients who did not smoke.

They found that smokers' tumors presented as a separate metabolic subtype of kidney cancer, with its own set of specific vulnerabilities. As a result, these patients could benefit from a tailored treatment strategy.

"Importantly, this integrated approach is key to identifying major metabolic reprogramming in energy and biosynthesis, which is associated with the presence of cadmium and inorganic arsenic found in cigarettes and the distinct signature of copper in tumours in smokers," says Maria Czyzyk Krzeska. .

Smokers will benefit from specialist treatment

A specialized treatment may lead to more favorable results, the study authors added. "There is a need for in-depth analysis of the metabolic subtypes of these cancers to determine the best way to treat each tumor," she said. . "This is one of the first studies to show that this kind of analysis is necessary. Personalization, or precision medicine, holds the promise of providing a specific and unique treatment based on the molecular observations of each patient's cancer. This has huge potential to transform patient outcomes, leading to better and longer lives."